# Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker

> **NCT00680680** · NA · COMPLETED · sponsor: **Franklin D. Gaylis, MD Inc.** · enrollment: 20 (estimated)

## Conditions studied

- Urinary Retention
- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Dutasteride

## Key facts

- **NCT ID:** NCT00680680
- **Lead sponsor:** Franklin D. Gaylis, MD Inc.
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-05
- **Primary completion:** 2008-02
- **Final completion:** 2008-02
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2008-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00680680

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00680680, "Treatment of Refractory Urinary Retention Secondary to Benign Prostatic Hyperplasia (BPH) With Dual Five Alpha Reductase Inhibition Combined With an Alpha Blocker". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00680680. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*